Total Payments
$203,050
2024 Payments
$17.75
Companies
8
Transactions
164
Medicare Patients
4,338
Medicare Billing
$49,925
Payment Breakdown by Category
Consulting$132,152 (65.1%)
Other$33,155 (16.3%)
Travel$18,025 (8.9%)
Research$10,967 (5.4%)
Education$5,314 (2.6%)
Food & Beverage$3,438 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $132,152 | 40 | 65.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $30,630 | 19 | 15.1% |
| Travel and Lodging | $18,025 | 47 | 8.9% |
| Unspecified | $10,967 | 12 | 5.4% |
| Education | $5,314 | 2 | 2.6% |
| Food and Beverage | $3,438 | 43 | 1.7% |
| Honoraria | $2,525 | 1 | 1.2% |
Payments by Type
General
$192,083
152 transactions
Research
$10,967
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $119,889 | 121 | $0 (2022) |
| BioMarin Pharmaceutical Inc. | $33,384 | 17 | $0 (2018) |
| SANOFI US SERVICES INC. | $17,370 | 5 | $0 (2021) |
| SANOFI-AVENTIS U.S. LLC | $15,281 | 7 | $0 (2021) |
| Spark Therapeutics, Inc. | $10,602 | 8 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,800 | 3 | $0 (2023) |
| Amicus Therapeutics, Inc. | $2,679 | 1 | $0 (2021) |
| Sumitomo Pharma America, Inc. | $47.01 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17.75 | 1 | Sumitomo Pharma America, Inc. ($17.75) |
| 2023 | $429.26 | 2 | Takeda Pharmaceuticals U.S.A., Inc. ($400.00) |
| 2022 | $10,112 | 13 | GENZYME CORPORATION ($10,112) |
| 2021 | $41,169 | 14 | GENZYME CORPORATION ($16,288) |
| 2020 | $32,176 | 18 | GENZYME CORPORATION ($20,307) |
| 2019 | $53,071 | 49 | GENZYME CORPORATION ($52,905) |
| 2018 | $27,208 | 25 | GENZYME CORPORATION ($11,316) |
| 2017 | $38,868 | 42 | BioMarin Pharmaceutical Inc. ($22,709) |
All Payment Transactions
164 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/20/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: UROLOGY | ||||||
| 07/27/2023 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $29.26 | General |
| Category: Urology | ||||||
| 02/08/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 09/09/2022 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Genetic Disease | ||||||
| 08/30/2022 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Genetic Disease | ||||||
| 06/22/2022 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,920.00 | General |
| 06/01/2022 | GENZYME CORPORATION | XENPOZYME (Biological) | Consulting Fee | Cash or cash equivalent | $2,584.00 | General |
| Category: Genetic Disease | ||||||
| 05/13/2022 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Genetic Disease | ||||||
| 05/13/2022 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Genetic Disease | ||||||
| 03/21/2022 | GENZYME CORPORATION | LUMIZYME (Biological) | Consulting Fee | Cash or cash equivalent | $608.00 | General |
| Category: Genetic Disease | ||||||
| 02/10/2022 | GENZYME CORPORATION | XENPOZYME (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-Controlled, Repeat Dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency • Category: Genetic Disease | ||||||
| 02/07/2022 | GENZYME CORPORATION | LUMIZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Genetic Disease | ||||||
| 02/07/2022 | GENZYME CORPORATION | NEXVIAZYME (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatment-naive Patients With Late-onset Pompe Disease • Category: Genetic Disease | ||||||
| 02/07/2022 | GENZYME CORPORATION | XENPOZYME (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-Controlled, Repeat Dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency • Category: Genetic Disease | ||||||
| 02/07/2022 | GENZYME CORPORATION | LUMIZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Genetic Disease | ||||||
| 02/01/2022 | GENZYME CORPORATION | NEXVIAZYME (Biological) | — | In-kind items and services | $250.00 | Research |
| Study: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatment-naive Patients With Late-onset Pompe Disease • Category: Genetic Disease | ||||||
| 11/21/2021 | GENZYME CORPORATION | — | — | In-kind items and services | $1,250.00 | Research |
| Study: A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatment-naive Patients With Late-onset Pompe Disease | ||||||
| 11/02/2021 | GENZYME CORPORATION | LUMIZYME (Biological) | Consulting Fee | Cash or cash equivalent | $2,128.00 | General |
| Category: Genetic Disease | ||||||
| 10/19/2021 | Amicus Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,678.50 | General |
| 10/08/2021 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $4,256.00 | General |
| 10/01/2021 | GENZYME CORPORATION | LUMIZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Genetic Disease | ||||||
| 09/28/2021 | GENZYME CORPORATION | LUMIZYME (Biological) | Consulting Fee | Cash or cash equivalent | $2,432.00 | General |
| Category: Genetic Disease | ||||||
| 09/23/2021 | GENZYME CORPORATION | LUMIZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Genetic Disease | ||||||
| 08/23/2021 | GENZYME CORPORATION | LUMIZYME (Biological) | Consulting Fee | Cash or cash equivalent | $1,824.00 | General |
| Category: Genetic Disease | ||||||
| 08/15/2021 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $9,424.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PHASE 1/2, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF A SINGLE INTRAVENOUS INFUSION OF SPK-3006 IN ADULTS WITH LATE-ONSET POMPE DISEASE | Spark Therapeutics, Inc. | $5,218 | 1 |
| Pompe Registry | GENZYME CORPORATION | $2,749 | 6 |
| A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatment-naive Patients With Late-onset Pompe Disease | GENZYME CORPORATION | $2,000 | 3 |
| A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-Controlled, Repeat Dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency | GENZYME CORPORATION | $1,000 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 5 | 1,399 | 1,624 | $99,281 | $15,085 |
| 2021 | 5 | 1,594 | 1,982 | $119,628 | $19,274 |
| 2020 | 5 | 1,345 | 1,509 | $93,215 | $15,566 |
Total Patients
4,338
Total Services
5,115
Medicare Billing
$49,925
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 357 | 373 | $26,110 | $3,935 | 15.1% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 360 | 376 | $17,672 | $2,975 | 16.8% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 267 | 270 | $19,980 | $2,448 | 12.3% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2022 | 76 | 248 | $10,168 | $1,798 | 17.7% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 119 | 127 | $5,207 | $937.35 | 18.0% |
| 94618 | Test for exercise-induced lung stress | Office | 2022 | 48 | 49 | $6,174 | $930.94 | 15.1% |
| 94618 | Test for exercise-induced lung stress | Facility | 2022 | 40 | 42 | $5,292 | $790.66 | 14.9% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2022 | 48 | 51 | $3,570 | $533.29 | 14.9% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2022 | 49 | 52 | $2,444 | $407.90 | 16.7% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2022 | 35 | 36 | $2,664 | $328.12 | 12.3% |
| 94726 | Determination of lung volumes using plethysmography | Office | 2021 | 385 | 415 | $29,050 | $4,565 | 15.7% |
| 94729 | Measurement of lung diffusing capacity | Office | 2021 | 385 | 415 | $19,505 | $3,417 | 17.5% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Facility | 2021 | 96 | 387 | $15,867 | $2,964 | 18.7% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Office | 2021 | 274 | 281 | $20,794 | $2,657 | 12.8% |
| 94618 | Test for exercise-induced lung stress | Facility | 2021 | 62 | 65 | $8,190 | $1,331 | 16.2% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2021 | 144 | 154 | $6,314 | $1,174 | 18.6% |
| 94618 | Test for exercise-induced lung stress | Office | 2021 | 54 | 57 | $7,182 | $1,169 | 16.3% |
| 94726 | Determination of lung volumes using plethysmography | Facility | 2021 | 79 | 86 | $6,020 | $946.83 | 15.7% |
| 94729 | Measurement of lung diffusing capacity | Facility | 2021 | 79 | 86 | $4,042 | $708.82 | 17.5% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Facility | 2021 | 36 | 36 | $2,664 | $341.28 | 12.8% |
| 94726 | Determination of lung volumes using plethysmography | Office | 2020 | 363 | 375 | $26,521 | $4,195 | 15.8% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Office | 2020 | 264 | 266 | $19,958 | $3,160 | 15.8% |
| 94729 | Measurement of lung diffusing capacity | Office | 2020 | 363 | 375 | $17,951 | $3,148 | 17.5% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Facility | 2020 | 61 | 167 | $6,847 | $1,310 | 19.1% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2020 | 110 | 117 | $4,797 | $900.95 | 18.8% |
About Dr. Kenneth Berger, M.D
Dr. Kenneth Berger, M.D is a Pulmonary Disease healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1659365880.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kenneth Berger, M.D has received a total of $203,050 in payments from pharmaceutical and medical device companies, with $17.75 received in 2024. These payments were reported across 164 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($132,152).
As a Medicare-enrolled provider, Berger has provided services to 4,338 Medicare beneficiaries, totaling 5,115 services with total Medicare billing of $49,925. Data is available for 3 years (2020–2022), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location New York, NY
- Active Since 09/02/2005
- Last Updated 08/09/2022
- Taxonomy Code 207RP1001X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1659365880
Products in Payments
- NO PRODUCT DISCUSSED (Drug) $38,969
- LUMIZYME (Biological) $36,097
- Vimizim (Biological) $31,545
- LUMIZYME (Drug) $20,407
- DISEASE STATE (Drug) $16,764
- XENPOZYME (Biological) $5,084
- MYOZYME (Drug) $4,240
- ELAPRASE (Biological) $3,400
- NEXVIAZYME (Biological) $750.00
- GEMTESA (Drug) $47.01
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in New York
Dr. Bisher Akil, M.d, M.D
Pulmonary Disease — Payments: $452,539
Pulmonary Disease $452,539
David Rapoport, M.d, M.D
Pulmonary Disease — Payments: $366,853
Pulmonary Disease $366,853
Peter Bach, Md, MD
Pulmonary Disease — Payments: $358,604
Pulmonary Disease $358,604
Jonathan Raskin, M.d, M.D
Pulmonary Disease — Payments: $323,538
Pulmonary Disease $323,538
Roxana Sulica, M.d.,, M.D.,
Pulmonary Disease — Payments: $269,071
Pulmonary Disease $269,071
Monica Kraft
Pulmonary Disease — Payments: $235,232
Pulmonary Disease $235,232